BioCentury
ARTICLE | Tools & Techniques

Using exosomes to switch myeloid cells

Codiak’s exosome therapies against STAT6, CEBPB effectively switch macrophages to kill cancer

December 5, 2019 9:06 PM UTC

Driven by the natural biology of exosomes, Codiak has moved beyond diagnostics and targeted cancer therapies to embrace myeloid switching as a strategy to treat cancer.

The biotech presented preclinical data Nov. 18 at the American Association for Cancer Research’s Special Conference on Tumor Immunology and Immunotherapy showing that ASO-carrying exosome therapies can be an effective monotherapy in cancer. ...